Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 6—June 2008

Dispatch

Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France

Svetlana Egorova*1, Mohammed Timinouni*2, Marie Demartin*, Sophie A. Granier†, Jean M. Whichard‡, Vartul Sangal§, Laëtitia Fabre*, Aurélia Delauné*, Maria Pardos*, Yves Millemann¶, Emmanuelle Espié#, Mark Achtman§**, Patrick A.D. Grimont*, and François-Xavier Weill*Comments to Author 
Author affiliations: *Institut Pasteur, Paris, France; †Agence Française de Sécurité Sanitaire des Aliments, Maisons-Alfort, France; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA; §Max-Planck-Institute für Infektionsbiologie, Berlin, Germany; ¶Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France; #Institut de Veille Sanitaire, Saint-Maurice, France; **University College, Cork, Ireland;

Main Article

Table

Resistance to specific antimicrobial drugs in Salmonella enterica serotype Newport from humans in France, 2000–2005*

Drug % Resistant isolates
2000 (n = 100) (N = 109) 2001 (n = 124) (N = 134) 2002 (n = 66) (N = 71) 2003 (n = 126) (N = 138) 2004 (n = 91) (N = 94) 2005 (n = 78) (N = 80)
Amoxicillin 27 9.7 1.5 19.8 8.8 3.8
Ceftriaxone/ceftazidime 15 4 1.5 17.5 2.2 0
Gentamicin 4 1.6 0 1.6 2.2 0
Nalidixic acid 23 7.3 4.5 1.6 4.4 2.6
Ciprofloxacin 0 0 0 0 0 0
Sulfonamides 29 10.5 4.5 19.8 8.8 0
Trimethoprim 10 4 3 1.6 4.4 0
Chloramphenicol 25 9.7 1.5 15.9 8.8 0
Tetracycline 27 11.3 3 19 9.9 3.8

*n, no. of isolates studied; N, no. of isolates received at the French National Reference Centre for Salmonella (1 per patient).

Main Article

1Current affiliation: Institut Pasteur, St. Petersburg, Russia.

2Current affiliation: Institut Pasteur, Casablanca, Morocco.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO